|Files in This Item:|
There are no files associated with this item.
|Title: ||Insulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms.|
|Affiliation: ||Neuropsychiatric Genetics Research Group, Department of Psychiatry, Trinity College Dublin, St. James Hospital, Dublin 8, Ireland.|
|Citation: ||Insulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms. 2012, 520 (1):51-6 Neurosci. Lett.|
|Journal: ||Neuroscience letters|
|Issue Date: ||27-Jun-2012 |
|PubMed ID: ||22609570|
|Abstract: ||Insulin-like growth factor-1 (IGF1) and its active peptide (1-3)IGF1 modulate brain growth and plasticity and are candidate molecules for treatment of brain disorders. IGF1 N-terminal portion is naturally cleaved to generate the tri-peptide (1-3)IGF1 (glycine-praline-glutamate). IGF1 and (1-3)IGF have been proposed as treatment for neuropathologies, yet their effect on nerve cells has not been directly compared. In this study we examine the effects of IGF1 and (1-3)IGF1 in primary cortical cultures and measure the expression levels of markers for intracellular pathways and synaptic function. We find that both treatments activate the IGF1 receptor and enhance the expression of synaptic markers, however, they activate different intracellular pathways. Furthermore, (1-3)IGF1 administration increases the expression of endogenous IGF1, suggesting a direct interaction between the two molecules. The results show that the two molecules increase the expression of synaptic proteins through activating different cellular mechanisms.|
Insulin-Like Growth Factor I
Mitogen-Activated Protein Kinases
Primary Cell Culture
Receptor, IGF Type 1
|Appears in Collections: ||St. James's Hospital|
All Items in LENUS are protected by copyright, with all rights reserved, unless otherwise indicated.